mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

LenioBio

More Like This

PR Newswire associated0

LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression

PR Newswire associated0

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production

LenioBio secures EUR 3.7M of EU4Health funding to develop ALiCE® for cost-effective and rapid production of protein-based medicines

PR Newswire associated0

LenioBio Appoints CTO and CCO to Spearhead Growth and Innovation

PR Newswire associated0

LenioBio Earns Prestigious EU STEP Seal: A Signal of Excellence for Investors

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions